Indication
EBV-related non-Hodgkin's lymphoma
2 clinical trials
6 products
Clinical trial
An Open-Label, Phase 2 Trial of Nanatinostat in Combination With Valganciclovir in Patients With Epstein-Barr Virus-Positive (EBV+) Relapsed/Refractory LymphomasStatus: Recruiting, Estimated PCD: 2025-07-01
Clinical trial
Constitutive IL7 (C7R) Modified EBV Specific T-Lymphocytes for Treatment of EBV-Positive LymphomaStatus: Recruiting, Estimated PCD: 2024-03-30
Product
Dose Level 1AProduct
Dose Level 2AProduct
Dose Level 2BProduct
Dose Level 3BProduct
Dose Level 3A